Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 21.1% year to date against the industry 's decline of 4.7%. The stock has outperformed the sector and the S&P 500 Index in this timeframe.
Gilead Outperforms Industry, Sector & S&P 500 Index
Gilead Sciences is a dominant player in the HIV market with market-leading treatments. Its diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases.
Approval of new drugs, encouraging pipeline progress and positive data readouts have boosted investors' sentiment in the past six months. However, the oncology business is under pressure.
Let's delve into GILD's strengths and weaknesses to analyze how to play the stock at present.
GILD's Leading HIV Franchise Will Continue Its Momentum
Gilead's flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has become the number-one prescribed regimen for both treatment-naïve and switch patients. Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum for GILD in the upcoming quarters.
Descovy (FTC 200 mg/TAF 25 mg) for pre-exposure prophylaxis (PrEP) is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States.
Gilead's efforts to innovate its HIV portfolio are impressive. Late-stage studies, PURPOSE 1 and PURPOSE 2, validated lenacapavir's potential to prevent HIV. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025.
The European Medicines Agency validated the Marketing Authorization Application and EU-Medicines for All application for twice-yearly lenacapavir for HIV prevention.
The successful development and potential approval of lenacapavir for the prevention of the disease should solidify Gilead's HIV franchise.
Per GILD, lenacapavir, with its twice-yearly dosing, could set a new bar for HIV prevention and allow PrEP to reach a larger number of people who could benefit from a prevention regimen.
Livdelzi Approval Strengthens GILD's Liver Disease Portfolio
The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC) has strengthened GILD's liver disease portfolio and validated its CymaBay acquisition. The drug's initial uptake is encouraging.
The candidate was approved under the brand name Livdelzi. Gilead also recently received conditional marketing authorization from the European Commission for seladelpar for the treatment of PBC.
Challenges for GILD's Oncology Business
Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025.
Breast cancer drug Trodelvy's sales were lower than expected in the first quarter due to inventory dynamics.
Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in progression-free survival in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors.
The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line mTNBC in 2026 will strengthen the company's oncology business.
GILD's Valuation and Estimate Revision
From a valuation standpoint, GILD is expensive. According to the price/earnings ratio, GILD's shares currently trade at 13.70x forward earnings, lower than the large-cap pharma industry's average of 14.62X but higher than its mean of 10.53X.
Earnings estimates for GILD have moved north in the past 60 days. The bottom-line estimate for 2025 has increased to $7.91 from $7.87, while that for 2026 has improved to $8.39 from $8.31.
Stay Invested in GILD
Large biotech companies are generally considered safe havens for investors interested in this sector as they are well equipped to weather the uncertain macroenvironment.
GILD is one of the dominant players in the HIV market. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. The potential launch of lenacapavir for PrEP in 2025 will be a significant boost for the company.
Gilead's strategic deals and acquisitions to diversify its business are encouraging. However, Biktarvy sales are expected to be under pressure due to Medicare Part D redesign, which, in turn, should impact overall HIV growth.
Hence, we advise prospective investors to wait and watch how well Biktarvy and the oncology business combat the existing headwinds before making a positive investment decision. In addition, we believe investors should also wait for better entry levels.
For investors already owning the stock, it's important to note that Gilead has been consistently increasing and paying out dividends. The company declared a quarterly dividend of $0.79 per share of common stock for the second quarter of 2025. Its strong cash position (as of March 31, 2025, GILD had $7.9 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.91% is sustainable.
Gilead presently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
42 minutes ago
- CTV News
Meta spending big on AI talent but will it pay off?
Mark Zuckerberg and Meta are spending billions of dollars for top talent to make up ground in the generative artificial intelligence race, sparking doubt about the wisdom of the spree. OpenAI boss Sam Altman recently lamented that Meta has offered $100 million bonuses to engineers who jump to Zuckerberg's ship, where hefty salaries await. A few OpenAI employees have reportedly taken Meta up on the offer, joining Scale AI founder and former chief executive Alexandr Wang at the Menlo Park-based tech titan. Meta paid more than $14 billion for a 49 percent stake in Scale AI in mid-June, bringing Wang on board as part of the deal. Scale AI labels data to better train AI models for businesses, governments and labs. 'Meta has finalized our strategic partnership and investment in Scale AI,' a Meta spokesperson told AFP. 'As part of this, we will deepen the work we do together producing data for AI models and Alexandr Wang will join Meta to work on our superintelligence efforts.' US media outlets have reported that Meta's recruitment effort has also targeted OpenAI co-founder Ilya Sutskever; Google rival Perplexity AI, and hot AI video startup Runway. Meta chief Zuckerberg is reported to have sounded the charge himself due to worries Meta is lagging rivals in the generative AI race. The latest version of Meta AI model Llama finished behind its heavyweight rivals in code writing rankings at an LM Arena platform that lets users evaluate the technology. Meta is integrating recruits into a new team dedicated to developing 'superintelligence,' or AI that outperforms people when it comes to thinking and understanding. 'Mercenary' Tech blogger Zvi Moshowitz felt Zuckerberg had to do something about the situation, expecting Meta to succeed in attracting hot talent but questioning how well it will pay off. 'There are some extreme downsides to going pure mercenary... and being a company with products no one wants to work on,' Moshowitz told AFP. 'I don't expect it to work, but I suppose Llama will suck less.' While Meta's share price is nearing a new high with the overall value of the company approaching $2 trillion, some investors have started to worry. Institutional investors are concerned about how well Meta is managing its cash flow and reserves, according to Baird strategist Ted Mortonson. 'Right now, there are no checks and balances' with Zuckerberg free to do as he wishes running Meta, Mortonson noted. The potential for Meta to cash in by using AI to rev its lucrative online advertising machine has strong appeal but 'people have a real big concern about spending,' said Mortonson. Meta executives have laid out a vision of using AI to streamline the ad process from easy creation to smarter targeting, bypassing creative agencies and providing a turnkey solution to brands. AI talent hires are a long-term investment unlikely to impact Meta's profitability in the immediate future, according to CFRA analyst Angelo Zino. 'But still, you need those people on board now and to invest aggressively to be ready for that phase' of generative AI, Zino said. According to The New York Times, Zuckerberg is considering shifting away from Meta's Llama, perhaps even using competing AI models instead. Penn State University professor Mehmet Canayaz sees potential for Meta to succeed with AI agents tailored to specific tasks at its platform, not requiring the best large language model. 'Even firms without the most advanced LLMs, like Meta, can succeed as long as their models perform well within their specific market segment,' Canayaz said.
CTV News
2 hours ago
- CTV News
Debate is underway in U.S. Senate on Trump's big bill. It may go all night
WASHINGTON —Debate is underway in the Senate for an all-night session Sunday, with Republicans wrestling President Donald Trump's big bill of tax breaks and spending cuts over mounting Democratic opposition -- and even some brake-pumping over the budget slashing by the president himself. The outcome from the weekend of work in the Senate remains uncertain and highly volatile. GOP leaders are rushing to meet Trump's Fourth of July deadline to pass the package, but they barely secured enough support to muscle it past a procedural hurdle in a tense scene the day before. A handful of Republican holdouts revolted, and it took phone calls from Trump and a visit from Vice President JD Vance to keep it on track. GOP Sen. Thom Tillis of North Carolina announced Sunday he would not seek reelection after Trump badgered him for saying he could not vote for the bill with its steep Medicaid cuts. A new analysis from the nonpartisan Congressional Budget Office found that 11.8 million more Americans would become uninsured by 2034 if the bill became law. It also said the package would increase the deficit by nearly $3.3 trillion over the decade. But other Senate Republicans, along with conservatives in the House, are pushing for steeper cuts, particularly to health care, drawing their own unexpected warning from Trump. 'Don't go too crazy!' the president posted on social media. 'REMEMBER, you still have to get reelected.' All told, the Senate bill includes some $4 trillion in tax cuts, making permanent Trump's 2017 rates, which would expire at the end of the year if Congress fails to act, while adding the new ones he campaigned on, including no taxes on tips. The Senate package would roll back billions in green energy tax credits that Democrats warn will wipe out wind and solar investments nationwide, and impose $1.2 trillion in cuts, largely to Medicaid and food stamps, by imposing work requirements and making sign-up eligibility more stringent. Additionally, the bill would provide a $350 billion infusion for border and national security, including for deportations, some of it paid for with new fees charged to immigrants. If the Senate can push through overnight voting and pass the bill, it would need to return to the House. Speaker Mike Johnson has told lawmakers to be on call for a return to Washington this coming week. Democrats ready to fight all night Unable to stop the march toward passage of the 940-page bill, the Democrats as the minority party in Congress is using the tools at its disposal to delay and drag out the process. Democrats forced a full reading of the text, which took some 16 hours, ending Sunday afternoon. Then senators took over the debate, filling the chamber with speeches, while Republicans largely stood aside. 'Reckless and irresponsible,' said Sen. Gary Peters of Michigan. 'A gift to the billionaire class,' said Sen. Bernie Sanders of Vermont. Sen. Patty Murray, the ranking Democrat on the Appropriations Committee, raised particular concern about the accounting method being used by the Republicans, which says the tax breaks from Trump's first term, in 2017, are now 'current policy' and the cost of extending them should not be counted toward deficits. 'In my 33 years here in the United States Senate, things have never -- never -- worked this way,' said Murray, the longest-serving Democrat on the Budget Committee. She said that kind of 'magic math' won't fly with Americans trying to balance their own household books. 'Go back home and try that game with your constituents,' she said. 'We still need to kick people off their health care -- that's too expensive. We still need to close those hospitals -- we have to cut costs. And we still have to kick people off SNAP -- because the debt is out of control.' Sanders said Tillis' decision not to seek reelection shows the hold that Trump's cult of personality has over the GOP. 'We are literally taking food out of the mouths of hungry kids,' Sanders said, while giving tax breaks to Jeff Bezos and other wealthy billionaires. GOP leaders unphased Republicans are using their majorities to push aside Democratic opposition, and appeared undeterred, even as they have run into a series of political and policy setbacks. 'We're going to pass the 'Big, beautiful bill,' said Sen. Lindsey Graham, R-S.C., the Budget Committee chairman. 'And President Trump is going to sign it.' The holdout Republicans remain reluctant to give their votes, and their leaders have almost no room to spare, given their narrow majorities. Essentially, they can afford three dissenters in the Senate, with its 53-47 GOP edge, and about as many in the House, if all members are present and voting. Trump, who has at times allowed wiggle room on his deadline, kept the pressure on lawmakers to finish. He threatened to campaign against Tillis, who was worried that Medicaid cuts would leave many without health care in his state. Trump badgered Tillis again on Sunday morning, saying the senator 'has hurt the great people of North Carolina.' Later Sunday, Tillis issued a lengthy statement announcing he would not seek reelection in 2026. Democrats can't filibuster, but can stall Using a congressional process called budget reconciliation, the Republicans can muscle the bill through on a simple majority vote in the Senate, rather than the typical 60-vote threshold needed to overcome objections. Without the filibuster, Democrats have latched on to other tools to mount their objections. One is the full reading of the bill text, which has been done in past situations. Democrats also intend to use their full 10 hours of available debate time, now underway. And then Democrats are prepared to propose dozens of amendments to the package that would be considered in an all-night voting session -- or all-day, depending on the hour. GOP senators to watch As Saturday's vote tally teetered, attention turned to Sen. Lisa Murkowski, R-Alaska, who was surrounded by GOP leaders in intense conversation. She voted 'yes.' Several provisions in the package are designed for her state in Alaska. A short time later, Majority Leader John Thune, R-S.D., drew holdouts Sen. Rick Scott of Florida, Mike Lee of Utah and Cynthia Lummis of Wyoming to his office. Vance joined in. The talks dragged on. Then Vance led them all back in to vote. Later, Scott said he had met with the president, adding, 'We all want to get to yes.' Lee said the group 'had an internal discussion about the strategy to achieve more savings and more deficit reduction, and I feel good about the direction where this is going, and more to come.'
CTV News
3 hours ago
- CTV News
ADVERTISEMENT Watch July 1 tariff deadline approaching, Canadian officials say trade negotiations to continue. Former foreign affairs minister Peter MacKay anticipates that Prime Minister Mark Carney will continue negotiations over the upcoming Canada Day holiday.
July 1 tariff deadline approaching, Canadian officials say trade negotiations to continue. Former foreign affairs minister Peter MacKay anticipates that Prime Minister Mark Carney will continue negotiations over the upcoming Canada Day holiday.
